Search Results 81-90 of 19329 for B cell lymphomas

  1. Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma - Mayo Clinic

    Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma · Overview · Participation eligibility · Participating Mayo Clinic ...

  2. Advancement in CAR-T cell therapy for resistant B cell cancers - Mayo Clinic

    — Hong Qin, M.D., Ph.D. CAR -T cell therapy has shown potential in achieving remission in some B-cell lymphomas and leukemias. Yet ...

  3. A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma - Mayo Clinic

    A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma · More about research at Mayo Clinic.

  4. Study of BMF-219, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

    ... B-cell Lymphoma (DLBCL), Multiple Myeloma (MM), and Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL). Print details. Share; Facebook ...

  5. Hodgkin Clinical Trials

    It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax ...

  6. A Study to Evaluate Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) - Mayo Clinic

    The purpose of tis study is to evaluate whether adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma ( ...

  7. Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma - Mayo Clinic

    ... Cell or Follicular B-Cell Lymphoma. Print details. Share; Facebook · Twitter. Overview; Participation eligibility; Participating Mayo Clinic info; More ...

  8. A Study Evaluating the Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Mayo Clinic

    Histologically proven large B-cell lymphoma including the following types defined by WHO 2016 (Swerdlow et al., 2016): · Relapsed or refractory disease after ...

  9. Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Relapsed/Refractory Large B-cell Lymphoma - Mayo Clinic

    T-cell/histiocyte rich large B-cell lymphoma;; DLBCL associated with chronic inflammation;; Primary cutaneous DLBCL, leg type;; Epstein-Barr virus (EBV) + ...

  10. Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) - Mayo Clinic

    The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia ...